Clareo Health | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female participants ≥ 18 years of age.
Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit.
HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits.
Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits.
History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for HS)
Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period.
Willingness to avoid pregnancy or fathering children.
You may not be if
Draining tunnel count of \> 20 at Screening or Baseline visits.
Women who are pregnant (or who are considering pregnancy) or breastfeeding.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
Evidence of infection with TB, HBV, HCV or HIV.
History of failure to JAK inhibitor treatment of any inflammatory disease.
Laboratory values outside of the protocol-defined ranges.
